Genetic Technologies Acquires EasyDNA To Expand Into Wellness Testing

  • Genetic Technologies Limited GENE has agreed to acquire EasyDNA's brand and distribution rights from BelHealth for $4 million in cash and stock.
  • EasyDNA currently sells paternity, oncology, and health & wellness genomics-based laboratory tests through agreements with 12 laboratories in North America, AsiaPac, and Europe.
  • In CY20, EasyDNA had total revenue of $4.63 million through online retail sales of its at-home DNA tests.
  • Under the terms of the agreement, the deal consideration comprises $2 million in cash, $1.5 million paid in GENE ADRs, and $500k in cash to be held in escrow payable to BelHealth.
  • EasyDNA revenue has grown by 11% in the last two years, and Gene will target opportunities for further growth.
  • Additionally, Genetic Technologies will be onboarding EasyDNA's existing team based in Malta and Australia. 
  • Price Action: GENE stock is up 1.16% at $3.50 during the premarket session on the last check Monday.
Market News and Data brought to you by Benzinga APIs
Posted In: M&ANewsPenny StocksHealth CareGeneralBriefs
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!